Taurunum Medical Journal
Sign in
Issue image

More articles from Volume 27, Issue 3, 2011

OrIGINaLNI radOVI OrIGINaL arTICLEs Gliomi mozga kod starijih pacijenata: astrocitomi, oligodendrogliomi i ependimomi

OrIGINaLNI radOVI OrIGINaL arTICLEs Analiza rezultata posthemioterapijske retroperitonealne limfadenektomije kod pacijenata sa intermedijarnim i lošim rizikom neseminomskih tumora testisa

OrIGINaLNI radOVI OrIGINaL arTICLEs Seksualno ponašanje studenata i percepcija rizika

OrIGINaLNI radOVI OrIGINaL arTICLEs Uticaj povišenih vrednosti aeropolutanata na egzacerbaciju akutnog napada astme kod dece u Pančevu u 2010 i 2011 godini

Neoplastic, hiperplastic or ectopic meningothelial islands? -Case report and short review of the literature

Article views


{{ submission.title }}

OrIGINaLNI radOVI OrIGINaL arTICLEs Analiza rezultata posthemioterapijske retroperitonealne limfadenektomije kod pacijenata sa intermedijarnim i lošim rizikom neseminomskih tumora testisa

Djordje Argirovic ,
Djordje Argirovic
View authors publications

Search this author on:

PubMed | Google Scholar
Aleksandar Argirovic
Aleksandar Argirovic
View authors publications

Search this author on:

PubMed | Google Scholar

Published: 01.12.2010.

Biochemistry

Volume 27, Issue 3 (2011)

pp. 352-360;

https://doi.org/10.5937/matmed1103352a

Abstract

Cilj ove studije je procena rezultata lečenja pacijenata sa intermedijarnim i lošim rizikom po kriterijumima “International Germ Cell Cancer Collaborative Group” (IGCCCG) metastatskih neseminomskih tumora testisa (NSTT) pomoću hemioterapije i retroperitonealne limfadenektomije (RPLA). U periodu od 1982do 2005, 82 pacijenta sa metastatskim NSTT, klasificiranih kao intermedijarna (65) i loša (17) rizična grupa po IGCCCG kriterijumima, su imali posthemioterapijsku (PH)-RPLA za srednje praćenje od 95meseci. Srednji dijametar RP rezidualne mase (RM) je iznosio 3.0 cm, 15 (18.3%) pacijenata je imalo povišene vrednosti tumorskih markera u serumu (TMS) pre PH-RPLA. Dvadeset i sedam (32.9%) pacijenata je iziskivalo administraciju hemioterapije druge linije, a kod 75 (91.5%) RP RM je kompletno resecirana. Retroperitonealna histološka analiza je pokazala prisustvo fibroze kod 20 (26%), teratoma kod 36 (42%) i vitalnog karcinoma kod 26 (32%), sa preživljavanjem u 76%, 80% i 38%, respektivno. Pacijenti podvrgnuti drugoj hemioterapijskoj liniji su imali signifikantno veću učestalost vitalnog karcinoma na PHRPLA (49% prema 24%)(P<0.001). Pacijenti sa lošim rizikom NSTT nisu imali signifikantno veću verovatnoću progresije (47% prema 55%)(P=0.5) i gori ishod (53% prema 69%)(P=0.2) nego sa intermedijarnim rizikom. Analiza pacijenata koji su primali hemioterapiju prve linije pokazuje signifikantno veću verovatnoću slobode progresije (VSP) (66% prema 41%) i bolje preživljavanje (74% prema 48%)(P<0.01) posle PH-RPLA nego oni koji su primili hemioterapiju druge linije. Konstatovano je bolje preživljavanje kod pacijenata sa prvom prema drugoj liniji hemioterapije pre PH-RPLA u pogledu nalaza na RP histologiji kod fibroze (94% prema 20%), teratoma (88% prema55%) i vitalnog karcinoma (54% prema 23%)(P<0.001). Ukupno, 5-godišnja VSP i preživljavanja su iznosili 57%(95% IP, 50%-62%) i 69%(95% IP, 61%-77%). Multivarijantna analiza je pokazala da nepotpuna resekcija (P<0.001), veličina PH RM (P=0.01) i nalaz teratoma i vitalnog karcinoma (p<0.01) na PH-RPLA predstavljaju nezavisne prediktivne faktore za recidiv bolesti. Pacijenti sa uznapredovalim NSTT imaju dug vremenski interval do progresije kada se hemioterapija kombinuje sa resekcijom RM. Naši nalazi ukazuju da odgovor tumora na hemioterapiju u kombinaciji sa kompletnom resekcijom svih RM, predstavlja garanci

Keywords

testicular tumors,

nonseminomatous,

chemotherapy,

surgery,

retroperitoneal lymphadenectomy

References

1.
Bosl G, Rj M. Testicular germ-cell cancer. N Engl j Med. 1997;242–53.
2.
Einhorn L, Williams Sd L, Pj. Evolution of optimal duration of chemotherapy of favorable-prognosis disseminated germ cell tumors: a southeastern Cancer study Group protocol. Clin Oncol. 1989;387–91.
3.
Seher H, Bosl G, Geller N, Cirrincone C, Whitmore W, Golbey. Impact of symptomatic interval on prognosis of patients with stage III testicular cancer. Urology. 1983;559–61.
4.
Stoter G. Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer; results from a European Organization for research on Treatment of Cancer Multinstitutional Phase II study. Cancer res. 1987;47–2714.
5.
Mead G. The International Germ Cell Conmsensus Classification; a new prognostic factor-based staging classification for metastatic germ cell tumours. Clin Oncol ( r Coll radiol). 1997;207–9.
6.
Donohue Jp, Einhorn L, Sd W. Cytoreductive surgery for metastatic testis cancer : consideration of timing and extent. Urol. 1980;876–90.
7.
Steyeberg E, Keizer E, Fossa Sd. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. Clin Oncol. 1995;1177–87.
8.
The role of adjunctive post-chemotherapy surgery for nonseminomatous germ-cell tumors; current concept and controversies. semin Oncol. 2002;267–71.
9.
Oldenburg, Gc, Lien H, Nn, Woehre H, Sd F. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residualtumor masses. j Clin Oncol. 2003;3310–7.
10.
Long-term follow-up of cisplatin combination chemotherapy in patients with disseminated non-seminomatous testicular tumors: is a post-chemotherapy retroperitoneal lymphadenectomy needed after complete resection? Eur Urol. 2011;(2):319.
11.
Pfister D, Bush J, Schreder M. Pathohistologic findings in patients with nonseminomatous germ cell tumours who undergo postchemotherapy retroperitoneal lymph node dissection for small tumors. Eur Urol. 2011;(2):319.
12.
Long term outcome after postchemotherapy retroperitoneal lymphadenectomy in patientswith residual teratoma. Eur Urol. 2010;(2):236.
13.
Baniel G, Messemer, Einhorn L. Late relapses of testicular cancer. Clin Oncol. 1995;1179–85.
14.
Late relapses following treatment for nonseminomatous testicular tumors according to single centerbased experience. Eur Urol. 2007;(2):157.
15.
Late relapses of germ testicular tumors: a population based experience over 23 years. Eur Urol Meet. 2007;(5):38.
16.
Pathologic findings and clinical outcome in patients undergoing retroperitoneal lymphadenectomy after multiple chemotherapy regimens for metastatic nonseminomatous testicular tumors. Materia Medica. 2011;(1):195–202.
17.
The impact of extra-retroperitoneal masses in patients with advanced nonseminomatous testicular tumors. Eur Urol. 2010;(6):539.
18.
Bs C. Management of post-chemotherapy extra-retroperitoneal residual masses. World j Urol. 2009;482–92.
19.
Fiyayi K, Tjulandin. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors, prognostic factors and role of postsurgery chemotherapy-results from an international study group. Clin Oncol. 2001;2647–57.
20.
Predicting recurrence following post-chemotherapy retroperitoneal lymphadenectomy for residual fibrosis and teratoma. Eur Urol. 2010;(6):540.
21.
Parkinson M, Fisher C. Postchemotherapy residual masses in germ cell tumor patients: content, clinical features, and prognosis. Medical research Council Testicular Tumor Working Party. Cancer. 1998;1409–19.
22.
Steyeberg E, Hj K, Zwartendijk. Prognosis after resection of residual masses following chemotherapy for metastatic nonseminomatous testicular cancer: a multivariate analysis. Br j Cancer. 1993;195–200.
23.
Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymphadenectomy. Eur Urol. 2010;(6):573.
24.
Motyer, Pietro V. Teratoma with malignant transformation: diverse malignant histologies in men with germ cell tumors. Urol. 1998;133–8.

Citation

Copyright

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Most read articles

Partners
TT Medik
Google Schoolar
DOAJ